Manila Times Business
Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum
Multi-System Improvements in Healthspan with PTC-2105 Treatment Translate into Associated Significant Increases in Cancer-Specific and Overall Survival HOUSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. ("Eos” or the "Company”), a biotechnology company developing first-in-class mitochondrial-targeted gerotherapeutics designed to improve body composition, physical function, and metabolic health by targeting the underlying biological mechanisms of aging, is attending the Sachs 2nd Annu
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
BC-Driven Breakthrough: TCL Solar's Value Leap from Wafer Leadership to Tier 1 Module Supplier
2h ago
Making Sustainability Count on World Environment Day: How Beko Focuses on Lowering Water and Energy Consumption from Factories to Homes
2h ago
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
2h ago
PropMarket Launches as the First Prop Firm Built for Prediction Markets
2h ago